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of patients with transferrin saturation ,20% and serum ferritinAnemia management of adult hemodialysis patients in the
concentration ,800 ng/mL, only 53% were prescribed intrave-U.S.: Results from the 1997 ESRD Core Indicators Project.
nous iron. Multivariate linear regression analysis revealed thatBackground. The Health Care Financing Administration’s
serum albumin, urea reduction ratio, age, and transferrin satu-End-Stage Renal Disease (ESRD) Core Indicators Project col-
ration were significantly positively associated with hematocrit.lects clinical information on prevalent adult patients receiving
in-center hemodialysis (HD) care in the United States to assess Epoetin alfa dose and serum ferritin concentration were sig-
the quality of care delivered. Although hematocrit values, nificantly and negatively associated with the hematocrit (P ,
transferrin saturations, and iron prescription practices have 0.001).
improved over the last five years, we sought to determine Conclusion. Although substantial improvements have been
whether continued opportunities for improvement of this do- made in anemia management for adult in-center HD patients
main of care exist. over the past five years, significant opportunities persist to
Methods. A random sample of 7292 adult in-center HD pa- improve iron prescription practices.
tients was selected. Dialysis facility staff provided clinical infor-
mation for the period of October through December 1996
for 6858 (94%) patients; complete laboratory information was
Of the processes of patient care that affect the survivalavailable from 4991 (73%) returned forms. Hematocrit values,
transferrin saturations, serum ferritin concentrations, epoetin and hospitalization frequency of end-stage renal disease
alfa dosing, and iron prescriptions were abstracted from patient (ESRD) patients, the correction of anemia is particularly
medical records to assess anemia management practices. useful for scrutiny. The principal measures of outcomeResults. The mean hematocrit for this cohort was 32.6 6
(hematocrit and/or hemoglobin) are routinely collected3.5%. Seventy-two percent of patients had hematocrit values
and are easy to interpret, and interventions are available.30%. Forty-two percent had hematocrit values of 33 to 36%,
and 10% were severely anemic (hematocrit ,28%). Ninety- to improve this measure. Multiple data sets have de-
four percent of the patients received epoetin alfa intravenously scribed a strong, reproducible statistical association be-
(i.v.) and 6% subcutaneously. The mean weekly dose was 202.4
tween odds of death and hemoglobin [1, 2]. Thus, anemia6 137.2 units/kg. The mean transferrin saturation was 27.4 6
is a predictable and correctable outcome measure for12.6%; 73% of patients had a mean transferrin saturation
$20%. The mean serum ferritin concentration was 386 6 422 ESRD patients that deserves monitoring. The National
ng/mL; 79 and 12% of patients had a serum ferritin concentra- Kidney Foundation’s Dialysis Outcomes Quality Initia-
tion of .100 and .800 ng/mL, respectively. Nine percent of tive (DOQI) Clinical Practice Guidelines for the Treat-the sample (N 5 434) had a transferrin saturation ,20% and
ment of Anemia of Chronic Renal Failure describe clini-serum ferritin concentration ,100 ng/mL. Regardless of the
cal performance goals for this process of patient carepatient’s transferrin saturation, approximately three fourths of
the patients received either oral or i.v. iron, and only approxi- [3]. These guidelines advocate benchmark hematocrit
mately one half of the patients received i.v. iron. Of the subset values of 33 to 36%, transferrin saturation $20%, serum
ferritin concentrations $100 ng/mL, and more wide-
spread use of parenteral iron.Key words: end-stage renal disease, hematocrit, erythropoietin, trans-
ferrin, serum ferritin, dialysis, iron. The Health Care Financing Administration’s (HCFA’s)
national ESRD Core Indicators Project profiles interme-
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bulatory peritoneal dialysis patients [4]. A principal goalÓ 2000 by the International Society of Nephrology
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of the ESRD Core Indicators Project is to identify cate- were examined using data from the 1997 ESRD Core
Indicators Project.gorical variability in intermediate outcomes of dialysis
care, such as the management and correction of anemia
with recombinant human erythropoietin (epoetin alfa) METHODS
and iron. After having identified patterns of variability,
Study design and patient selectionthe goal at the level of the provider of dialysis services
The study design and sampling strategy used in theis to facilitate the recognition of opportunities for the
ESRD Core Indicators Project are described in detailimprovement of care [5]. In the case of anemia manage-
elsewhere [4, 10]. Briefly, all Medicare-eligible, adultment, this translates into optimizing the hematocrit with
ESRD patients receiving in-center HD on December 31,epoetin alfa and iron therapy. Using the DOQI Clinical
1996, were eligible for inclusion in the sample. A randomPractice Guidelines as clinical performance goals, the
sample of patients, stratified by the ESRD Networks,ESRD Core Indicators Project indicates that substantial
was drawn. The sample size (N 5 7292) was estimatedimprovement has occurred in the management of anemia
to provide a 95% confidence interval of 65% for ESRDfrom late 1993 to late 1996 [4]. The mean hematocrit for
Network-specific estimates.adult in-center HD patients increased from 30.5% in
October through December 1993 to 32.7% in October
Data collection
through December 1996. The proportion of patients with
Patient demographic and clinical information weremean hematocrit values .30% increased from 46% in
collected for the months of October to December 1996,late 1993 to 72% in late 1996. The proportion of HD
including the first monthly recorded hematocrit value,patients with severe anemia, defined as a mean hemato-
transferrin saturation, and serum ferritin concentration.crit value ,28%, declined from 23 to 10% over this same
Other abstracted information relating to anemia man-time period. These data are consistent with observations
agement practices included the prescribed weekly epoe-from other databases. For example, the U.S. Renal Data
tin alfa dose and route of administration and informationSystem (USRDS) reported in its 1997 Annual Report
regarding the type and route of iron administration.that as of the last quarter of 1995, the mean and median
Other clinical information abstracted from the patients’hematocrit values among epoetin alfa-treated patients
charts included first monthly predialysis and postdialysiswere 31.4 and 32.0%, respectively [6]. From 1993 to 1996,
blood urea nitrogen (BUN) concentration and predial-the mean epoetin alfa dose increased from approxi-
ysis and postdialysis body weight (kg) to calculate themately 10,500 to 14,350 units per week [7].
urea reduction ratio (URR) and single-pool Kt/V (calcu-Despite these improvements in the hematocrit of adult
lated using the second-generation formula of Daugirdas
HD patients, opportunities remain for improvement in
[11]), delivered HD time at the session the BUN mea-
the management of anemia. In the aforementioned surements were drawn, and first monthly serum albumin
HCFA report, the percentage of adult HD patients with concentration [measured by either the bromcresol green
a hematocrit of 33 to 36% was only 42% [4]. The USRDS (BCG) or the bromcresol purple (BCP) assay]. Informa-
investigators observed that more than 50% of epoetin tion on the relative timing of doses of intravenous iron
alfa-treated patients were iron deficient [8, 9]. The and the measurement of the transferrin saturation and
USRDS reported that in 1993, 25% of dialysis patients serum ferritin concentrations was not captured. Valida-
received no form of iron supplementation, and only tion of the abstracted data was conducted by Network
11.2% received intravenous iron [9]. Arguably, further personnel on a random 5% patient sample by review of
improvement in anemia management can be achieved the medical charts. No significant differences were found
by improvement in this parameter. This is particularly in the abstraction of the data for any clinical measure
significant in view of the attenuated effect of epoetin [12].
alfa in the absence of optimal iron stores [1, 2] and the
large Medicare expenditures for this hormone (approxi- Data analysis
mately $1.5 billion per year) [6]. Regional analysis of Patients with missing laboratory data were excluded
the ESRD Core Indicators data has shown significant from further analysis. Because of the small number of
variation among ESRD Networks for several anemia- samples processed using the BCP assay, the final data
related clinical parameters, such as hematocrit values, analysis was restricted to the preponderance of patients
transferrin saturations, serum ferritin concentrations, whose serum albumin concentrations were determined
and patterns of iron administration [4]. Toward identi- by the BCG laboratory method only (83%). The average
fying specific domains of anemia management that may value of each clinical parameter was calculated from
be targets for national quality-improvement initiatives, the values available over the three-month observation
practice patterns for epoetin alfa and iron administration period and was used for subsequent analyses. Simple
descriptive statistical analysis was performed for the ini-among adult, in-center HD patients in the United States
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Table 1. Descriptive characteristics of the study populationtial characterization of anemia management practices.
For some analyses, transferrin saturations and serum Characteristic N (%)
ferritin concentrations were divided at clinically relevant Total 4991 (100)
Gendercut points. Bivariate analyses, including chi-square, two-
Male 2619 (52)tailed Student t-tests, and hierarchical analysis of vari-
Female 2372 (48)
ance (ANOVA), were conducted to determine associa- Race
Caucasian 2534 (51)tions between variables. Mean values are presented as
African American 1857 (37)the mean 6 sd. A two-tailed P value , 0.01 was consid-
Other 600 (12)
ered significant. Linear correlations were performed to Age (yrs)
Median 62.0test for associations between mean hematocrit and sev-
Meana 59.9615.3eral variables of interest.
Primary diagnosis
Multivariate linear regression analysis was performed Diabetes mellitus 1924 (38)
Hypertension 1403 (28)in a stepwise fashion to adjust simultaneously for poten-
Glomerulonephritis 669 (13)tial confounding variables and to identify independent
Other/unknown 995 (20)
variables associated with hematocrit. Variables entered Years on dialysis
Median 2.2into the regression model included gender, race (Cauca-
Meana 3.463.6sian and African American only), age, mean prescribed
Clinical measures (mean)
weekly epoetin alfa dose (units/kg predialysis body wt/ URR 67.1%67.3%
Kt/Vb 1.3560.27week), mean transferrin saturation, mean serum ferritin
Serum albumin 3.860.39concentration, mean URR, mean serum albumin con-
a Mean 6 sdcentration, duration of dialysis (years), predialysis body
b Kt/V calculated by the Daugirdas II formula [11]
weight (kg), and whether the patient had been prescribed
intravenous iron at least once during the three-month
study period.
tients (18- to 44-year-old) had significantly lower hema-All data analyses were performed using Epi Info (ver-
tocrit values compared with older patients (P , 0.001),sion 6.04) [13] and SPSS for Windows (version 6.1) [14].
despite having significantly higher prescribed weekly
epoetin alfa doses (P , 0.001). A significant variation
RESULTS was seen among the ESRD Networks for the percentage
The dialysis facility response rate was 94% (6858 out of patients with hematocrit values $33%, ranging from
of 7292). Complete laboratory information was available 41 to 62% (P , 0.001; Fig. 1). Significant differences in
from 4991 (73%) of the returned forms that formed mean hematocrit, prescribed epoetin alfa doses, mean
the final sample for analysis. There were no significant transferrin saturation values, and mean serum ferritin
differences in patient demographic characteristics in the concentration were noted by category of Kt/V values.
group of patients with complete data and the group of Patients with Kt/V ,1.2 had significantly lower mean
patients with incomplete data. The descriptive character- hematocrit, prescribed epoetin alfa doses, transferrin sat-
istics of the final patient group are listed in Table 1. The uration values, and serum ferritin concentration com-
group was 52% male, 51% Caucasian, and 37% African pared with patients with Kt/V $1.2 (Table 2). Linear
American and had a median age of 62 years. Thirty- correlation analysis revealed a positive linear relation-
eight percent of the patients had diabetes mellitus as a ship between mean hematocrit and mean Kt/V (r 2 5
primary cause of ESRD. 0.01, P , 0.001).
The mean hematocrit value for the sample for analysis Greater serum albumin concentrations were associ-
was 32.6 6 3.5%, which was increased from 30.5 6 3.9% ated with higher hematocrit values across all demo-
in 1993 (P , 0.001). Seventy-two percent of patients graphic categories (Tables 2 and 3). Linear correlation
had hematocrit values of .30%. Forty-two percent of analysis revealed a positive linear relationship between
patients had hematocrit values of 33 to 36%, and 10% the mean hematocrit and mean serum albumin concen-
of patients had a mean hematocrit value of ,28%. Al- tration (r 2 5 0.034, P , 0.001). Stratification by quartiles
though no difference was observed for hematocrit values of serum albumin revealed a similar inverse relationship
between men and women, this was at the expense of between serum albumin concentration and epoetin alfa
approximately 20% more epoetin alfa prescribed to dosing. Patients with serum albumin concentrations in
women (P , 0.001; Table 2). Caucasians had, on average, the lowest and highest quartile were prescribed, on aver-
higher hematocrit values than African Americans (P , age, 234.3 units/kg/week and 186.6 units/kg/week of
0.01), although each were prescribed the same amount epoetin alfa, respectively (P , 0.01). The mean serum
of epoetin alfa. However, the clinical significance of the albumin concentrations of patients in the lowest and
highest quartiles were 3.2 and 4.2 m/dL, respectivelyracial difference in hematocrit was small. Younger pa-
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Table 2. Mean hematocrit values, prescribed epoetin alfa doses, and iron status by selected patient and clinical care parameters
Serum % of Patients with
Hematocrit Epoetin dose Transferrin sat % of Patients with ferritin serum ferritin
% units/kg/week % transferrin Sat $20% ng/mL $100 ng/mL
Total 32.6 202.4 27.4 73 385.8 79
Gender
Male 32.6 186.8b 27.5 73 365.1b 78
Female 32.5 219.5 27.2 72 408.6 80
Race
Caucasian 32.7a 199.2 27.1 72 380.5 78
African American 32.4 204.3 27.6 73 395.4 81
Age years
18–44 32.1b 222.3b 29.3b 74 353.7a 73b
45–64 32.6 195.5 27.0 72 380.0 80
651 32.8 200.1 27.0 72 403.4 81
Primary diagnosis
Diabetes mellitus 32.7 192.5b 26.4b 72a 370.6 80
Hypertension 32.6 201.8 27.3 72 379.6 80
Glomerulonephritis 32.6 208.8 28.8 78 393.6 77
Other/unknown 32.6 217.9 28.6 72 418.6 78
Years on dialysis
,0.5 31.4a 209.1 24.1b 56b 283.2a 72b
0.5–1 32.7 194.5 27.7 73 325.1 76
1–2 32.8 193.5 27.0 72 380.6 81
21 32.7 206.6 28.1 76 423.3 81
Kt/V quartile
,1.2 31.9b 197.5b 26.7a 68b 357.4b 76a
1.2–1.35 32.8 193.5 27.1 73 360.3 78
1.36–1.5 32.7 199.4 27.4 73 387.8 80
.1.5 32.9 218.0 28.4 77 435.2 82
Serum albumin g/dL
,3.00 30.2b 260.1b 29.8b 69b 537.2b 87
3.00–3.49 31.7 241.1 25.9 64 390.7 77
3.50–3.79 32.6 197.6 27.2 72 385.2 79
3.80–4.09 33.0 189.9 27.4 75 372.2 79
4.101 33.1 186.6 28.6 79 377.0 80
Network quartile
(by mean hematocrit)
1 (lowest) 32.1b 188.0b 27.6 73 380.2 80
2 32.4 208.8 27.2 71 386.9 77
3 32.7 210.1 27.8 73 380.1 80
4 33.1 201.7 27.1 74 394.2 80
a P , 0.01 and b P , 0.001, statistically significant differences between patient characteristic groups
Fig. 1. Percentage of patients with hemato-
crit values $33% by ESRD Networks. Sig-
nificant difference among Networks, P ,
0.001.
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Table 3. Mean hematocrit values by selected patient characteristics, stratified by serum ferritin concentration, transferrin saturation,
prescribed weekly epoetin alfa dose, and serum albumin concentration
Mean hematocrit value %
Gender
Race
Age group years
African
Males Females Caucasians Americans 18–44 45–64 651
Total 32.6 32.5 32.7a 32.4 32.1b 32.5 32.8
Serum ferritin concentration quartile
1 32.8a 32.3 32.5 32.7 32.3 32.4 32.9
2 32.8 32.8 33.0 32.5 32.5 32.7 33.0
3 32.5 32.6 32.6 32.4 31.9 32.5 32.8
4 (highest) 32.4 32.5 32.7a 32.0 31.6a 32.5 32.6
Transferrin saturation category
,20% 31.8 31.9 32.1a 31.5 31.0b 31.6 32.4
20–25.69% 32.6 32.5 32.6 32.5 32.1 32.6 32.7
25.75–32.99% 33.0 33.0 32.9 33.0 32.6 32.9 33.2
33%1 33.3 32.9 33.2 32.8 32.7 33.3 33.2
Weekly epoetin alfa dose (units/kg) quartilec
1 32.6 32.5 32.7 32.4 32.2 32.5 32.8
2 32.0 32.2 32.2 32.0 31.5a 32.1 32.3
3 31.5 31.8 31.8 31.4 31.1b 31.4 32.1
4 (highest) 30.8 30.9 31.1a 30.5 30.3a 30.7 31.3
Serum albumin concentration
,3.5 g/dL 31.0 31.4 31.4 30.8 29.9b 31.2 31.6
$3.5 g/dL 32.9 32.8 33.0 32.7 32.4b 32.8 33.1
a P , 0.01 and b P , 0.001, Statistically significant differences within patient demographic subgroups for each level of the clinical parameter
c For the subset of patients with hematocrit ,36%
(P , 0.001). There was a significant positive association with the lowest mean hematocrit values also had signifi-
cantly lower prescribed doses of epoetin alfa (P , 0.001)between predialysis body weight and serum albumin con-
centrations (r 2 5 0.0065, P , 0.001). Employing stepwise compared with the other quartiles of Networks (Table
2). No other statistically significant correlations werelinear regression that used the predialysis body weight
and serum albumin concentration as independent vari- noted.
Mean hematocrit values stratified by weekly pre-ables and weekly epoetin alfa dose as the dependent
variable, a stronger association of predialysis body scribed epoetin alfa dose (units/kg), categories of trans-
ferrin saturation, serum ferritin concentration, and se-weight compared with serum albumin concentration was
observed (F statistic 415.4 vs. 249.6, respectively). Strati- rum albumin concentration are presented in Table 3.
Indifferent of the demographic category, the hematocritfication by quartiles of predialysis body weight revealed
an inverse relationship between body weight and epoetin tended to be lower at higher epoetin alfa doses. Similarly,
the hematocrit tended to increase as transferrin satura-alfa dosing. Patients in the lowest quartile of body weight
were prescribed on average 260.6 units/kg of epoetin alfa tion increased from ,20 to 32.9%. Among the subset
of patients with transferrin saturation ,20%, Africanweekly, whereas patients in the highest quartile were
prescribed on average 157.8 units/kg weekly (r 2 5 0.8657, American and younger patients (18 to 44 years) were
again observed to have lower hematocrit values thanP , 0.01). The mean predialysis weights of the patients
in the lowest and highest quartile were 54.1 and 100.0 Caucasians and older patients (P , 0.01 and P , 0.001,
respectively). No clear trends were observed for the in-kg, respectively (P , 0.001).
Ninety-four percent of the patients were prescribed teraction between the serum ferritin concentration, de-
mographics, and the hematocrit.epoetin alfa intravenously and 6% subcutaneously. The
mean prescribed weekly epoetin alfa dose was 202.4 6 During the three-month period of observation, 27%
of the patients had transferrin saturations ,20%. The137.2 units/kg. Within the subset of patients with hemato-
crit values of ,36%, an inverse relationship existed be- mean transferrin saturation value for all patients in the
sample was 27.4% (6 12.6%). The frequency distribu-tween prescribed epoetin alfa doses and hematocrit val-
ues, with smaller doses associated with higher hematocrit tion of transferrin saturations is illustrated in Figure 2.
Twenty-one percent of the patients had a serum ferritinvalues (r 2 5 0.044, P , 0.001; Table 3). There was a
significant geographic variation in the mean prescribed concentration of ,100 ng/mL. The mean serum ferritin
concentration for all patients was 386 ng/mL (6 422weekly epoetin alfa doses. Among ESRD Networks, pre-
scribed epoetin alfa doses ranged from 172.8 to 242.0 U/ ng/mL). Seventy-nine percent and 12% of the patients
had a serum ferritin concentration $100 ng/mL andkg/week (P , 0.001). The quartile of ESRD Networks
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Fig. 2. Frequency distribution profile of
mean transferrin saturation.
Table 4. Categories of iron status for the sample
Patients %
Transferrin saturation $20% 73
Transferrin saturation ,20% 27
Serum ferritin concentration $100 ng/mL 79
Serum ferritin concentration ,100 ng/dL 21
Serum ferritin concentration $100–800 ng/mL 68
Serum ferritin concentration .800 ng/mL 12
Transferrin saturation ,20% and serum ferritin
concentration ,100 ng/mL 9
Transferrin saturation ,20% and serum ferritin
concentration $100–800 ng/mL 17
Transferrin saturation ,20% and serum ferritin
concentration .800 ng/mL 2
.800 ng/mL, respectively (Table 4). Only 9% of the
patients (N 5 434) had “absolute iron deficiency,” de-
fined as a transferrin saturation of ,20% and serum Fig. 3. Bivariate relationship between the mean hematocrit and the
mean transferrin saturation (R2 5 0.0104).ferritin concentration ,100 ng/mL [3, 15, 16]. Because
the patients in this cohort were not observed for longer
than three months and the erythropoietic response to
parenteral iron was not available, it was not possible to mean transferrin saturation yielded an r 2 of only 0.0004
accurately distinguish the functional iron deficiency from (not significant). Patients with higher hematocrit values
inflammation/infectious etiologies of a low transferrin tended to have greater transferrin saturations (r 2 5
saturation and normal to elevated serum ferritin concen- 0.0104, P , 0.001). The bivariate relationship between
tration. However, for this report, “relative iron defi- transferrin saturation and hematocrit is illustrated in Fig-
ciency” was defined as a transferrin saturation ,20% ure 3. The subset of patients with transferrin saturation
and a serum ferritin concentration between 100 and 800 $20% had higher mean hematocrit values compared
ng/mL (17% of the patients; Table 4). Most patients fell with patients with transferrin saturation ,20%, that is,
into this category. 32.9 vs. 31.8%, respectively (P , 0.001).
Patients with transferrin saturation values ,20% were Patients with a mean hematocrit ,28% had higher
prescribed on average 218.2 units/kg of epoetin alfa per serum ferritin concentration than those with a mean he-
week compared with patients with transferrin saturation matocrit $28% (P , 0.001). Of patients with a mean
values $20%, who were prescribed on average 196.4 hematocrit ,28%, 15% had a serum ferritin concentra-
U/kg per week (P , 0.001). Linear regression analysis tion .800 ng/mL compared with 13% of those patients
with a mean hematocrit value .36% (not significant;of the mean prescribed weekly epoetin alfa dose versus
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Table 5. Mean transferrin saturation, serum ferritin concentration, higher transferrin saturation values (P , 0.001) com-
and categories of transferrin saturation and serum ferritin
pared with patients with serum albumin values $3.0concentration by categories of hematocrit
g/dL (Table 2). Among the subset of patients with a
Mean transferrin saturation serum ferritin concentration .800 ng/mL, the mean se-All patients 27.4
rum albumin concentrations for patients with transferrinHematocrit category
,28% 26.2a saturation ,20% and $20% were 3.65 and 3.75 g/dL,
28%–32% 26.1 respectively (P 5 NS).33%–36% 28.4
Although 77% of the patients were prescribed either.36% 30.3
Patients with transferrin saturation $20% oral or intravenous iron at least once during the three-
All patients 73% month study period, only 54% of patients were pre-Hematocrit category
scribed intravenous iron. When the patients were catego-,28% 60%a
28%–32% 69% rized into those with a transferrin saturation $20% and
33%–36% 78%
,20% (73 and 27% of the sample, respectively), the
.36% 79%
results were almost identical across categories (Table 6).Serum ferritin concentration ng/mL
All patients 386 Among the subset of patients with transferrin saturations
Hematocrit category
,20%, only 78% were prescribed either oral or intrave-
,28% 471a
nous iron at least once during the three months. Only28%–32% 376
33%–36% 375 54% of these patients were prescribed intravenous iron.
.36% 393 Two hundred and ninety-eight (22%) of the 1363 pa-Patients with serum ferritin concentration $100 ng/mL
tients with transferrin saturations ,20% were not pre-All patients 79%
Hematocrit category scribed iron by any route of administration. Among the
,28% 80% subset of patients with transferrin saturations $20%,28%–32% 78%
only 77% were prescribed either oral or intravenous iron33%–36% 80%
.36% 77% at least once during the three months. Fifty-four percent
Patients with serum ferritin concentration .800 ng/mL of this subset were prescribed intravenous iron, and 23%All patients 12%
were not prescribed iron by any route of administration.Hematocrit category
,28% 15% Two hundred and seventy-two (26%) of the 1037 pa-
28%–32% 11% tients with serum ferritin concentrations ,100 ng/mL33%–36% 11%
were not prescribed iron by any route of administration..36% 13%
Analysis of the subgroup of patients with a mean hema-a Significant differences among hematocrit categories within groups, P , 0.001
tocrit ,36% revealed similar patterns of iron prescrip-
tion.
Of the 9% of the patient sample with absolute iron
deficiency (transferrin saturation ,20% and a serum
Table 5). The mean hematocrit for patients with a trans-
ferritin concentration ,100 ng/mL), only 38% were pre-
ferrin saturation ,20% and serum ferritin concentration scribed intravenous iron. Chi-square analysis of all the
.800 ng/mL was 31.6%, not significantly different from patients and of the subset of patients with transferrin
the group with absolute iron deficiency (31.9%). Fifty- saturations ,20% revealed no significant difference in
one percent of patients in this sample for analysis had the percentage of patients prescribed intravenous iron by
transferrin saturation $20% and a serum ferritin concen- categories of hematocrit. The percentage of patients pre-
tration between 100 and 800 ng/mL. The mean hemato- scribed intravenous iron varied significantly by ESRD
crit for this subset was 32.9%, significantly higher than Network, ranging from 40 to 68% (P , 0.001). Similarly,
the mean hematocrit values for the other two subsets there was significant variability by ESRD Network in
(P , 0.001). Figure 4 displays the association between the percentage of patients with a transferrin saturation
quartile of prescribed weekly epoetin alfa dose and mean ,20% and a serum ferritin concentration ,100 ng/mL
hematocrit, by category of transferrin saturation. There that were prescribed intravenous iron (16 to 92%,
was a consistent inverse relationship between prescribed P , 0.001).
weekly epoetin alfa dose and hematocrit value, with The results of the multivariate linear regression analy-
higher hematocrit values as transferrin saturation in- sis evaluating the association between several patient
creased for all quartiles of weekly epoetin alfa doses. As characteristics and laboratory clinical parameters with
the transferrin saturation increased, the effect of epoetin hematocrit are summarized in Table 7. The overall r 2 of
alfa on hematocrit status was attenuated. the final model was 0.101, indicating that approximately
Patients with serum albumin values ,3.0 g/dL had 10% of the variability in hematocrit values was ac-
significantly lower mean hematocrit values (P , 0.001), counted for by the variables that remained in the model.
Patient gender, race, and weight did not remain in thehigher serum ferritin concentrations (P , 0.001), and
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Fig. 4. Relationship between the mean he-
matocrit and quartiles of weekly epoetin alfa
doses by transferrin saturation category. Sig-
nificant differences among mean values by
epoetin dose quartile, P , 0.01.
Table 6. Patterns of iron administration by categories of transferrin saturation and serum ferritin concentration
All patients
Transferrin saturation ,20% Transferrin saturation $20%
Percent of patients Percent of patients
Oral iron 40b Oral iron 35
Intravenous iron 38b Intravenous iron 42
Both 16a Both 12
Neither 22 Neither 23
Serum ferritin concentration ,100 ng/mL Serum ferritin concentration .800 ng/mL
Percent of patients Percent of patients
Oral iron 47b Oral iron 29
Intravenous iron 29b Intravenous iron 43
Both 10 Both 14
Neither 26 Neither 27
Patients with hematocrit ,36%
Transferrin saturation ,20% Transferrin saturation $20%
Percent of patients Percent of patients
Oral iron 41b Oral iron 35
Intravenous iron 38b Intravenous iron 42
Both 16 Both 13
Neither 22 Neither 23
Serum ferritin concentration ,100 ng/mL Serum ferritin concentration .800 ng/mL
Percent of patients Percent of patients
Oral iron 48b Oral iron 30
Intravenous iron 28b Intravenous iron 43
Both 11 Both 14
Neither 26 Neither 27
a Statistically significant differences between iron stores groups, P , 0.01
b Statistically significant differences between iron stores groups, P , 0.001
final model nor did years on dialysis or the prescription tion, and age were all positively associated with hemato-
of intravenous iron. In this model, each decade of in- crit (P , 0.001).
creasing age was associated with an increase in hemato-
crit of 0.23%. In this model, weekly prescribed epoetin
DISCUSSIONalfa dose and serum ferritin concentration were inversely
Strategies for optimal anemia management have beenassociated with hematocrit (P , 0.001), whereas the
URR, serum albumin concentration, transferrin satura- reported in the DOQI Clinical Practice Clinical Guide-
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Table 7. Variables associated with hematocrit by multivariate linear regression analysisa
Regression
Variable F statistic coefficient se of coefficient
Epoetin alfa dose (1000 units/kg/week) 188 24.4 0.37
Albumin g/dL 162 1.45 0.127
URR % 130 4.91 0.690
Age decade 108 0.23 0.03
Transferrin saturation % 94 0.028 0.004
Serum ferritin ng/mL 82 26.02 3 104 0.00012
All P values are ,0.001.
aVariables included in the model: patient gender, race (Caucasian and African American only), age, mean prescribed weekly epoetin alfa dose (units/kg pre-
dialysis body wt), mean transferrin saturation, mean serum ferritin concentration, mean URR, mean serum albumin concentration, duration of dialysis (years), pre-
dialysis body weight (kg), and whether the patient had been prescribed intravenous iron at least once during the three month study period.
lines for the Treatment of Anemia of Chronic Renal powerful predictor than in other analyses [1, 17], perhaps
because of more variability of dose in our sample. An-Failure [3]. These guidelines advocate target hematocrit
values of 33 to 36%, transferrin saturation $20%, serum other possibility is that previous investigators included
other normalizing variables (that is, creatinine and anionferritin concentrations $100 ng/mL, and more wide-
spread use of intravenous iron. Data from the ESRD gap [1]) in their model. Serum albumin was the predictor
most positively associated with increasing hematocrit,Core Indicators Project and the USRDS demonstrate
continual improvement in the hematocrit of American followed by URR, age, and transferrin saturation. The
inclusion of laboratory surrogates of nutrition like creati-HD patients since the availability of epoetin alfa [4, 6,
8]. However, this increment in hematocrit has occurred nine and anion gap, along with URR in the model, would
diminish some of the predictive power of URR. Ourin the setting of an approximately 120% increase in epoe-
tin alfa doses from 1990 to 1996 [7]. The finding of an findings are consistent with those of other investigators,
who have reported a similar association of serum albu-inverse relationship between the epoetin alfa dose and
hematocrit has been observed in other data sets and min and age with hematocrit [1]. In this analysis, the
transferrin saturation, a measure of iron availability tomay, in part, reflect physician prescribing patterns in the
setting of a hematocrit-linked ceiling for epoetin alfa the marrow for hemoglobin synthesis [15, 16], was simi-
larly observed to predict hematocrit, as has been re-reimbursement and differential hormone responsive-
ness [1]. ported by others [1].
In addition to the aforementioned statistical link be-This analysis, derived from a nationally representative
patient database, identifies an important area for im- tween laboratory surrogates of iron stores and hemato-
crit, previous intervention studies have demonstrated theprovement, and a complimentary strategy for affecting
it that is within the domain of the dialysis care team, that impact of iron deficiency on anemia correction in the
absence and presence of epoetin alfa [1, 19–22]. Foris, correction of iron deficiency. Twenty-eight percent of
the prevalent patients did not achieve a mean hematocrit some ESRD patients, partial anemia correction has been
observed with vigorous repletion of iron alone, that is,of 30%. Only 42% of the patients had mean hematocrit
values within the target range of 33 to 36%, as recom- in the absence of epoetin alfa [1, 22]. Supporting this
interpretation is the observation that patients with highermended by the DOQI Clinical Practice Guidelines for
the Treatment of Anemia of Chronic Renal Failure [3]. hematocrit values had greater transferrin saturations.
This study demonstrates that indifferent of the categoryPreviously reported demographic trends and statistical
linkages to hematocrit [1, 3, 17, 18] were noted in the of epoetin alfa dose, higher percentages of transferrin
saturation were associated with higher hematocrit val-current database, strengthening the validity of the obser-
vations reported herein. ues. For patients receiving the largest doses of epoetin
alfa, increasing the transferrin saturation had the sameFactors other than iron therapy may be manipulated
to potentially improve the hematocrit, and thus should effect on the hematocrit as was observed with lower
epoetin alfa doses in the setting of adequate iron reple-similarly be included in continuous quality-improvement
initiatives for anemia. An example is the dose of HD. tion. As anticipated, the percentage of patients with
transferrin saturation $20% increased with greater he-It was striking that patients with inadequate delivered
doses of HD (Kt/V ,1.2) also had significantly lower matocrit values, and patients with transferrin saturation
,20% tended to receive higher doses of epoetin alfa.hematocrits and prescribed epoetin alfa doses and iron
parameters. The concordance of these findings suggests Although iron management for American dialysis pa-
tients has improved [8], it is still not optimal. Becausea possible need in care that crosses multiple domains of
service. The dialysis dose was observed to be a more of substantial ongoing iron losses associated with the
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provision of HD, most HD patients cannot have their hematocrits as men, but at the expense of higher epoetin
alfa doses; and (d) nondiabetics have equivalent hemato-iron needs met by oral iron alone [1, 23–25]. However,
during the 90-day period of observation, approximately crits as diabetics, but require more epoetin alfa. The
statistical associations between race, gender, and hema-25% of this nationally representative base of patients
received no iron supplements. Even among the 27% of tocrit are unsurprising in that similar patterns have been
observed in healthy populations [1, 31, 32]. However,patients with overt iron deficiency, defined as a trans-
ferrin saturation ,20%, approximately one fourth of for the Core Indicators’ ESRD patients, there were no
gender differences in iron stores like in healthy persons.these received no iron supplements. If parenteral iron
replacement is viewed as a best clinical intervention for Therefore, relative epoetin unresponsiveness among
women secondary to iron deficiency seems not to accountiron deficiency [3], approximately 50% of the patients
were not treated by this strategy. In that a similar pattern for this difference. The direct relationship between in-
creasing age and hematocrit may be a reflection of theof iron replacement was observed for patients with trans-
ferrin saturations $20%, it appears that laboratory sur- discrepancy between prescribed and delivered epoetin
alfa doses. The data analysis provided herein is based onrogates of iron stores were not a principal determinant of
when or how to intervene with iron replacement therapy. prescribed doses. Because epoetin alfa is administered as
part of the HD treatment, it is subject to the limitationsThis practice pattern is surprising in view of the routine
availability of parenteral iron, a supportive reimburse- of HD compliance. If patients miss HD sessions, they
do not receive their epoetin alfa. In that younger patientsment mechanism for parenteral iron, a facile means of
intradialytic administration [25, 26] and a low incidence miss dialysis sessions more often than older patients [33],
the latter would be expected to have higher hematocritof significant acute side-effects [27]. Concern for long-
term toxicity has been raised by a recent retrospective values. Alternatively, age-associated differences in blood
pressure may have affected epoetin alfa dosing. The rela-analysis using HCFA billing data that suggested a delete-
rious correlation between putative dosing schedules for tively reduced dose of epoetin alfa needed by diabetics
is a novel finding. Patients with diabetes mellitus haveintravenous iron dextran and mortality, especially sec-
ondary to infectious events (abstracts; Collins et al, J often been excluded from intervention trials, and thus,
the basis for this counter-intuitive finding is unexplained.Am Soc Nephrol 8:190A, 1997, and Collins et al, J Am
Soc Nephrol 9:205A, 1998). However, these findings have The lower hematocrit values for patients relatively new
to HD may reflect: (a) late patient referral to nephrolo-not been validated in other data sets [28, 29]. Therefore,
iron administration is a domain of care that is readily gists, resulting in an inability to start epoetin alfa in a
timely fashion prior to the initiation of chronic dialysiswithin the dialysis team’s control [30].
Because clinical practice in 1996 did not include wide- therapy [34]; (b) epoetin alfa resistance secondary to
uremia [35]; (c) a high prevalence of comorbid conditionsspread use of weekly or monthly maintenance intrave-
nous iron therapy, it is possible that the three-month that impact epoetin alfa responsiveness, such as vascular
surgeries, and/or limit its administration, such as inade-study period did not capture iron use in some patients
dosed less frequently. The Core Indicators data set does quately controlled hypertension; and/or (d) continued
activity of the original disease that resulted in ESRD,not collect information on the timing of intravenous iron
administration with respect to the measurement of trans- such as systemic lupus erythematosus and hemolytic–
uremic syndrome.ferrin saturations. However, the bias invoked by this
data limitation would favor higher transferrin satura- Not all HD patients will respond to iron replacement
therapy alone [22, 30, 36]. The multivariate analysis de-tions, thus strengthening our contention that continued
improvement is possible in iron management. scribed that approximately 90% of the variability in the
hematocrit was accounted for by factors not included inHowever, this data set also illustrates that some com-
ponents of anemia correction may be more difficult for the model. Variables not included in the multivariate
model that may impact the hematocrit are the presencethe dialysis care team to identify and thus control. For
example, this national data set did not identify regional of severe hyperparathyroidism [37, 38], aluminum intoxi-
cation [39, 40], folate and vitamin B12 deficiencies [41],differences in measures of iron availability that corre-
lated with the geographic variability in hematocrit. This and particularly, comorbid conditions associated with
blood loss, such as vascular access surgery and gastroin-negative correlation suggests that the other elements that
affect hematocrit may be defined by geographic regions. testinal bleeding.
Recent reports have noted that laboratory surrogatesFurther investigation of this and other associations is
needed using data sets with more extensive elements. of an acute inflammatory state, such as the C-reactive
protein (CRP), are also powerful statistical predictorsOther examples of inadequately understood associations
are that: (a) African Americans have lower hematocrits of the response to epoetin alfa [18]. Patients with higher
levels of CRP had lower hematocrit and albumin valuesthan Caucasians; (b) younger patients have lower hema-
tocrits than older patients; (c) women have equivalent and higher serum ferritin concentrations. Therefore, the
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hematocrit and albumin may behave as negative acute- suggested values, and the data presented herein suggest
that many patients would benefit from even higher trans-phase reactants. In this analysis, patients with serum
albumin values ,3.0 g/dL had significantly lower mean ferrin saturation values. Third, monitoring for iron defi-
hematocrit values, higher serum ferritin concentrations, ciency is not difficult, and corrective strategies are readily
and lower transferrin saturation values compared with available. Finally, substantial systematic cost savings may
patients with serum albumin values $3.0 g/dL. These be effected through improved anemia correction and its
findings indicate that a subset of ESRD patients may beneficial effect on patient morbidity and mortality, and
have an inflammatory disorder or functional iron defi- by enhancing the effectiveness of epoetin alfa with iron
ciency that compromises their response to epoetin [15, (abstract; Collins et al, J Am Soc Nephrol 18:190A, 1997)
16]. Functional iron deficiency or inflammation was the [1–3, 42, 43]. Furthermore, as demonstrated by the analy-
predominant disorder, rather than absolute iron defi- sis presented herein, national patterns of anemia correc-
ciency. For many ESRD patients, epoetin alfa-stimulated tion, with attention to provision of adequate dialysis
erythropoiesis provokes iron utilization at a rate that and serum albumin levels, can and should be routinely
exceeds iron delivery. Many of these patients will have tracked as local and regional CQI strategies are imple-
an erythropoietic response to parenteral iron therapy mented.
(defined as either an increase in hematocrit and/or a
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